NASDAQ:GDRX GoodRx (GDRX) Stock Price, News & Analysis $7.71 -0.28 (-3.50%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$7.70▼$8.0650-Day Range$6.78▼$9.0552-Week Range$4.14▼$9.26Volume779,186 shsAverage Volume1.48 million shsMarket Capitalization$2.89 billionP/E RatioN/ADividend YieldN/APrice Target$9.36 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get GoodRx alerts: Email Address GoodRx MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside21.4% Upside$9.36 Price TargetShort InterestBearish10.16% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.36Based on 5 Articles This WeekInsider TradingSelling Shares$83,921 Sold Last QuarterProj. Earnings Growth53.33%From $0.15 to $0.23 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.26 out of 5 starsMedical Sector470th out of 910 stocksData Processing & Preparation Industry30th out of 56 stocks 3.3 Analyst's Opinion Consensus RatingGoodRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 9 buy ratings, 4 hold ratings, and 1 sell rating.Amount of Analyst CoverageGoodRx has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about GoodRx's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.16% of the float of GoodRx has been sold short.Short Interest Ratio / Days to CoverGoodRx has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in GoodRx has recently increased by 4.45%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldGoodRx does not currently pay a dividend.Dividend GrowthGoodRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GDRX. Previous Next 1.3 News and Social Media Coverage News SentimentGoodRx has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for GoodRx this week, compared to 6 articles on an average week.Search InterestOnly 5 people have searched for GDRX on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GoodRx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $83,921.00 in company stock.Percentage Held by InsidersOnly 4.17% of the stock of GoodRx is held by insiders.Percentage Held by Institutions63.77% of the stock of GoodRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GoodRx's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for GoodRx are expected to grow by 53.33% in the coming year, from $0.15 to $0.23 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GoodRx is -770.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GoodRx is -770.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioGoodRx has a PEG Ratio of 3.74. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGoodRx has a P/B Ratio of 4.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about GoodRx's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm Press Fmr CIA Advisor reveals PEACEMAKER superweaponKamala cannot get the “codes” to this superweapon. In Trump’s hands, it will restore America’s global dominance. It could also help Americans struggling under Bidenomics by potentially sending 5 military stocks SOARING. Historically, similar stocks have shot up 16,270% in just 18 months.Full details are in this announcement. About GoodRx Stock (NASDAQ:GDRX)GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.Read More GDRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GDRX Stock News HeadlinesSeptember 4 at 4:41 AM | insidertrades.comGoodRx Holdings, Inc. (NASDAQ:GDRX) Major Shareholder Sells $83,921.22 in StockSeptember 6 at 11:07 PM | finance.yahoo.comWhy Big Pharma is betting on telehealth strategiesSeptember 7, 2024 | Paradigm Press (Ad) Fmr CIA Advisor reveals PEACEMAKER superweaponKamala cannot get the “codes” to this superweapon. In Trump’s hands, it will restore America’s global dominance. It could also help Americans struggling under Bidenomics by potentially sending 5 military stocks SOARING. Historically, similar stocks have shot up 16,270% in just 18 months.September 5 at 5:25 AM | americanbankingnews.comEquity Vii L.P. Spectrum Sells 10,677 Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) StockAugust 16, 2024 | benzinga.comGoodRx Holdings Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)August 16, 2024 | markets.businessinsider.comRBC Capital Keeps Their Buy Rating on GoodRx Holdings (GDRX)August 15, 2024 | forbes.comA Consumerized Diagnostic: Looking Back And Ahead On A Decade Of CologuardAugust 15, 2024 | finance.yahoo.comInsider Sale: Chief Accounting Officer Romin Nabiey Sells 79,000 Shares of GoodRx Holdings Inc ...September 7, 2024 | Paradigm Press (Ad) Fmr CIA Advisor reveals PEACEMAKER superweaponKamala cannot get the “codes” to this superweapon. In Trump’s hands, it will restore America’s global dominance. It could also help Americans struggling under Bidenomics by potentially sending 5 military stocks SOARING. Historically, similar stocks have shot up 16,270% in just 18 months.August 9, 2024 | markets.businessinsider.comSteady Growth and Resilience Drive Buy Rating for GoodRx HoldingsAugust 9, 2024 | markets.businessinsider.comGoodRx Holdings: Hold Rating Amidst Operational Strengths and Market UncertaintiesAugust 9, 2024 | msn.comGoodRx Holdings, Inc. (NASDAQ:GDRX) Q2 2024 Earnings Call TranscriptAugust 8, 2024 | seekingalpha.comGoodRx Holdings, Inc. (GDRX) Q2 2024 Earnings Call TranscriptAugust 8, 2024 | finance.yahoo.comGoodRx Reports Second Quarter 2024 ResultsAugust 8, 2024 | markets.businessinsider.comGoodRx Holdings Faces Headwinds: Sell Rating Justified by Customer Decline and Revenue ConcernsAugust 8, 2024 | markets.businessinsider.comGoodRx Reports Better Q2 Revenue; Updates Annual Outlook Below ViewAugust 8, 2024 | msn.comGoodRx Reports Q2 Earnings With Increased Prescription Revenue But Subscription ChallengesAugust 8, 2024 | msn.comGoodRx (GDRX) Q2 2024 Earnings Call TranscriptSee More Headlines Receive GDRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GoodRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Data processing & preparation Sub-IndustryBusiness Services Current SymbolNASDAQ:GDRX CUSIPN/A CIK1809519 Webwww.goodrx.com Phone855-268-2822FaxN/AEmployees950Year FoundedN/APrice Target and Rating Average Stock Price Target$9.36 High Stock Price Target$16.00 Low Stock Price Target$4.50 Potential Upside/Downside+21.4%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($0.01) Trailing P/E RatioN/A Forward P/E Ratio51.40 P/E Growth3.74Net Income$-8,870,000.00 Net Margins-7.57% Pretax Margin-7.65% Return on Equity3.63% Return on Assets1.72% Debt Debt-to-Equity Ratio0.96 Current Ratio7.32 Quick Ratio7.32 Sales & Book Value Annual Sales$775.09 million Price / Sales3.73 Cash Flow$0.40 per share Price / Cash Flow19.14 Book Value$1.76 per share Price / Book4.38Miscellaneous Outstanding Shares375,205,000Free Float359,559,000Market Cap$2.89 billion OptionableOptionable Beta1.38 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Trevor Bezdek (Age 46)Co-founder & Chairman Comp: $537kMr. Douglas Joseph Hirsch (Age 53)Co-founder, Chief Mission Officer & Director Comp: $507.29kMr. Karsten Ian Voermann (Age 54)CFO & Principal Financial Officer Comp: $693.69kMr. Romin Nabiey (Age 36)Chief Accounting Officer & Principal Accounting Officer Comp: $516kMr. Scott W. Wagner (Age 53)Interim CEO & Principal Operating Officer Mr. Mike WalshPresident & Executive VP of Prescription MarketplaceMs. Whitney NotaroVice President of Investor RelationsMs. Gracye ChengGeneral Counsel & SecretaryMr. Andrew Slutsky (Age 37)Chief Marketing Officer Comp: $864.8kMs. Vina M. Leite (Age 54)Chief People Officer More ExecutivesKey CompetitorsDada NexusNASDAQ:DADAPegasystemsNASDAQ:PEGAZendeskNYSE:ZENFTAI AviationNYSE:FTAIToastNYSE:TOSTView All CompetitorsInsiders & InstitutionsEquity Vii L.P. SpectrumSold 10,677 sharesTotal: $83,921.22 ($7.86/share)Algert Global LLCBought 16,456 shares on 8/16/2024Ownership: 0.048%Susquehanna Fundamental Investments LLCSold 8,900 shares on 8/15/2024Ownership: 0.015%AQR Capital Management LLCBought 29,741 shares on 8/15/2024Ownership: 0.012%Deerfield Management Company L.P. Series CBought 22,123 shares on 8/15/2024Ownership: 0.006%View All Insider TransactionsView All Institutional Transactions GDRX Stock Analysis - Frequently Asked Questions How have GDRX shares performed this year? GoodRx's stock was trading at $6.70 at the beginning of 2024. Since then, GDRX shares have increased by 15.1% and is now trading at $7.71. View the best growth stocks for 2024 here. How were GoodRx's earnings last quarter? GoodRx Holdings, Inc. (NASDAQ:GDRX) released its earnings results on Thursday, August, 8th. The company reported $0.08 earnings per share for the quarter, missing analysts' consensus estimates of $0.09 by $0.01. GoodRx's revenue for the quarter was up 5.7% on a year-over-year basis. When did GoodRx IPO? GoodRx (GDRX) raised $900 million in an initial public offering on Wednesday, September 23rd 2020. The company issued 34,600,000 shares at a price of $24.00-$28.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and Barclays acted as the underwriters for the IPO and BofA Securities, Citigroup, Credit Suisse, RBC Capital Markets, UBS Investment Bank, Cowen, Deutsche Bank Securities, Evercore ISI, Citizens Capital Markets, KKR, LionTree, Raymond James, SVB Leerink, Academy Securities, Loop Capital Markets, R. Seelaus and Ramirez were co-managers. Who are GoodRx's major shareholders? Top institutional investors of GoodRx include Millennium Management LLC (1.10%), Rubric Capital Management LP (1.00%), Renaissance Technologies LLC (0.79%) and American Century Companies Inc. (0.62%). Insiders that own company stock include Scott Wagner, Equity Vii LP Spectrum, Idea Men, Llc, Abdiel Capital Management, Llc, Trevor Bezdek, Agnes Rey-Giraud, Babak Azad, Karsten Voermann, Bansi Nagji, Andrew Slutsky and Douglas Joseph Hirsch. View institutional ownership trends. How do I buy shares of GoodRx? Shares of GDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of GoodRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that GoodRx investors own include Gilead Sciences (GILD), NVIDIA (NVDA), AbbVie (ABBV), Bristol-Myers Squibb (BMY), DraftKings (DKNG), GW Pharmaceuticals (GWPH) and Rocket Companies (RKT). This page (NASDAQ:GDRX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GoodRx Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GoodRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
